» Articles » PMID: 35118003

Bacterial Vaginosis: What Do We Currently Know?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The vaginal microbiome is a well-defined compartment of the human microbiome. It has unique conditions, characterized by the dominance of one bacterial species, the This microbiota manifests itself by a low degree of diversity and by a strong dynamic of change in its composition under the influence of various exogenous and endogenous factors. The increase in diversity may paradoxically be associated with dysbiosis, such as bacterial vaginosis (BV). BV is the result of a disturbance in the vaginal ecosystem; i.e., a sudden replacement of by anaerobic bacteria such as , and others. It is the most common cause of vaginal discharge in women of childbearing age, approximately 30% of all causes. The etiology of this dysbiosis remains unknown, but its health consequences are significant, including obstetrical complications, increased risk of sexually transmitted infections and urogenital infections. Its diagnosis is based on Amsel's clinical criteria and/or a gram stain based on the Nugent score. While both of these methods have been widely applied worldwide for approximately three decades, Nugent score are still considered the "gold standard" of BV diagnostic tools. Given the limitations of these tools, methods based on molecular biology have been developed as alternative rational strategies for the diagnosis of BV. The treatment of BV aims at restoring the balance of the vaginal flora to stop the proliferation of harmful microorganisms. Prescription of antibiotics such as metronidazole, clindamycin, etc. is recommended. Faced with the considerable uncertainty about the cause of BV, the high rate of recurrence, the unacceptable treatment options, and clinical management which is often insensitive and inconsistent, research on this topic is intensifying. Knowledge of its composition and its associated variations represents the key element in improving the therapeutic management of patients with the most suitable treatments possible.

Citing Articles

Cannabidiol (CBD) Acts as an Antioxidant on , Resulting in Reduced Metabolic Activity, Loss of Survivability, and Elimination of Biofilms.

Sionov R, Korem M, Polacheck I, Steinberg D Antibiotics (Basel). 2025; 14(2).

PMID: 40001381 PMC: 11851883. DOI: 10.3390/antibiotics14020136.


Sexually transmitted infections and bacterial vaginosis in women of child-bearing age in Antananarivo, Madagascar: prevalence and risk factors from a cross-sectional study.

Fortas C, Harimanana A, Rasoanandrianina S, Rasoanaivo T, Razanadranaivo H, Mangahasimbola R BMC Infect Dis. 2025; 25(1):262.

PMID: 39994573 PMC: 11849146. DOI: 10.1186/s12879-025-10578-2.


Sialidases derived from Gardnerella vaginalis remodel the sperm glycocalyx and impair sperm function.

Dohadwala S, Shah P, Farrell M, Politch J, Marathe J, Costello C bioRxiv. 2025; .

PMID: 39975358 PMC: 11838519. DOI: 10.1101/2025.02.01.636076.


Diverse vaginal microbiota in healthy Japanese women: a combined relative and quantitative analyses.

Ito M, Kataoka M, Sato Y, Nachi H, Nomoto K, Okada N Front Cell Infect Microbiol. 2025; 14:1487990.

PMID: 39967801 PMC: 11832463. DOI: 10.3389/fcimb.2024.1487990.


Comparing the efficacy of probiotic plus antibiotic with the Antibiotic Therapy alone on the recurrence of Bacterial Vaginosis.

Ashraf S, Haroon A, Fayyaz A Pak J Med Sci. 2025; 41(1):125-129.

PMID: 39867779 PMC: 11755309. DOI: 10.12669/pjms.41.1.9922.


References
1.
Briselden A, Moncla B, Stevens C, Hillier S . Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J Clin Microbiol. 1992; 30(3):663-6. PMC: 265128. DOI: 10.1128/jcm.30.3.663-666.1992. View

2.
Schwebke J, Desmond R . A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2006; 44(2):213-9. DOI: 10.1086/509577. View

3.
Hooven T, Randis T, Hymes S, Rampersaud R, Ratner A . Retrocyclin inhibits Gardnerella vaginalis biofilm formation and toxin activity. J Antimicrob Chemother. 2012; 67(12):2870-2. PMC: 3494843. DOI: 10.1093/jac/dks305. View

4.
Fredricks D, Fiedler T, Marrazzo J . Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005; 353(18):1899-911. DOI: 10.1056/NEJMoa043802. View

5.
Bradshaw C, Brotman R . Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis. 2015; 15:292. PMC: 4518586. DOI: 10.1186/s12879-015-1027-4. View